Anti-SLC30A6 monoclonal antibody

Pre-made anti-SLC30A6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SLC30A6/SLC30A6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1697-Ab-1/ GM-Tg-hg-IP1697-Ab-2Anti-Human SLC30A6 monoclonal antibodyHuman
GM-Tg-rg-IP1697-Ab-1/ GM-Tg-rg-IP1697-Ab-2Anti-Rat SLC30A6 monoclonal antibodyRat
GM-Tg-mg-IP1697-Ab-1/ GM-Tg-mg-IP1697-Ab-2Anti-Mouse SLC30A6 monoclonal antibodyMouse
GM-Tg-cynog-IP1697-Ab-1/ GM-Tg-cynog-IP1697-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC30A6 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1697-Ab-1/ GM-Tg-felg-IP1697-Ab-2Anti-Feline SLC30A6 monoclonal antibodyFeline
GM-Tg-cang-IP1697-Ab-1/ GM-Tg-cang-IP1697-Ab-2Anti-Canine SLC30A6 monoclonal antibodyCanine
GM-Tg-bovg-IP1697-Ab-1/ GM-Tg-bovg-IP1697-Ab-2Anti-Bovine SLC30A6 monoclonal antibodyBovine
GM-Tg-equg-IP1697-Ab-1/ GM-Tg-equg-IP1697-Ab-2Anti-Equine SLC30A6 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1697-Ab-1/ GM-Tg-hg-IP1697-Ab-2; GM-Tg-rg-IP1697-Ab-1/ GM-Tg-rg-IP1697-Ab-2;
GM-Tg-mg-IP1697-Ab-1/ GM-Tg-mg-IP1697-Ab-2; GM-Tg-cynog-IP1697-Ab-1/ GM-Tg-cynog-IP1697-Ab-2;
GM-Tg-felg-IP1697-Ab-1/ GM-Tg-felg-IP1697-Ab-2; GM-Tg-cang-IP1697-Ab-1/ GM-Tg-cang-IP1697-Ab-2;
GM-Tg-bovg-IP1697-Ab-1/ GM-Tg-bovg-IP1697-Ab-2; GM-Tg-equg-IP1697-Ab-1/ GM-Tg-equg-IP1697-Ab-2
Products NameAnti-SLC30A6 monoclonal antibody
Formatmab
Target NameSLC30A6
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SLC30A6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1697-Ag-1Recombinant multi-species ZNT6/ SLC30A6/ MST103 protein


    Target information

    Target IDGM-IP1697
    Target NameSLC30A6
    Gene ID55676,210148,298786,709161,475716,101087917,518111,100070614
    Gene Symbol and Synonyms9530029F08Rik,MST103,MSTP103,SLC30A6,ZNT6
    Uniprot AccessionQ6NXT4,Q0VC54
    Uniprot Entry NameZNT6_HUMAN,ZNT6_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseOvary Cancer
    Gene EnsemblENSG00000152683
    Target ClassificationN/A

    The target: SLC30A6, gene name: SLC30A6, also named as MST103, MSTP103, ZNT6. This gene encodes a member of a family of proteins that function as zinc transporters. This protein can regulate subcellular levels of zinc in the Golgi and vesicles. Expression of this gene is altered in the Alzheimer's disease brain plaques. [provided by RefSeq, Aug 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.